Top news of the week: 25.02.2021.
Startups
Analysis: Bubbles, bubbles bound for trouble?
The $6.2 billion-an-hour rise in the value of world stocks since March was dubbed the "mother of all asset bubbles" by BofA analysts last week - and all of a sudden there is a high-pitched ...
Chutes & Ladders—Zimmer Biomet calls on Medtronic vet Jamali to lead spinout
Zimmer Biomet tagged a new chief executive for its upcoming spinout. Moncef Slaoui is joining Centessa Pharmaceuticals as chief scientific officer. Affinia bagged two additions to its R&D ...
In conversation with John Leonard, CEO of Intellia
Intellia CEO John Leonard discusses his journey from Abbott and AbbVie to a gene editing biotech and where he sees the field going in the near future.
Clover raises $230M as COVID-19 vaccine nears phase 3, multivariant prospect gets going
Clover Biopharmaceuticals has raised $230 million to take a COVID-19 vaccine candidate into a phase 2/3 clinical trial. The series C positions the Chinese biotech to validate the efficacy ...
Supporting the Rise of Biomanufacturing in Massachusetts will Ensure the Sustainability of the State of Possible
Home to the world’s top biopharma companies, leading universities and medical centers, a robust startup ecosystem, and hundreds of biotech companies, Massachusetts is the best place in the ...
Big Pharma-backed antibiotic R&D fund lands another $140M, bringing total haul above $1B
The AMR Action Fund has raised another $140 million to support antibiotic development. The cash adds to the almost $1 billion committed by around 20 biopharma companies, giving the fund the ...
Novavax Announces Memorandum of Understanding with Gavi for Cumulative Supply to COVAX Facility of 1.1 Billion Doses of COVID-19 Vaccine
Advances joint commitment from Novavax, Serum Institute of India and Gavi to ensure equitable access to NVX-CoV2373 worldwide across low-, middle- and high-income countries …
COVID-19 won’t be our last pandemic. Here’s how Biden can prepare us for the next one - Roll Call
OPINION — By taking critical actions to bolster our biotech economy, Biden can not only lead us out of this pandemic but better prepare us for the next one.